Production (Stage)
REGENXBIO Inc.
RGNX
$10.35
$1.5016.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 80.70% | -7.66% | -15.14% | -8.18% | -20.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 80.70% | -7.66% | -15.14% | -8.18% | -20.90% |
| Cost of Revenue | 36.21% | 38.37% | -110.80% | -108.89% | -106.96% |
| Gross Profit | 58.17% | -12.58% | 187.42% | 182.70% | 157.19% |
| SG&A Expenses | -11.71% | -18.42% | -17.30% | -11.14% | -2.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 176.97% | 117.88% | 101.03% | 102.28% | 102.32% |
| Total Operating Expenses | -9.43% | -11.31% | -8.33% | -7.14% | -5.99% |
| Operating Income | 39.49% | 12.55% | 5.66% | 6.76% | -0.32% |
| Income Before Tax | 39.42% | 13.86% | 8.30% | 12.02% | 3.71% |
| Income Tax Expenses | -- | -- | -253.49% | -253.49% | -253.49% |
| Earnings from Continuing Operations | 39.38% | 13.81% | 8.34% | 12.07% | 3.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.38% | 13.81% | 8.34% | 12.07% | 3.75% |
| EBIT | 39.49% | 12.55% | 5.66% | 6.76% | -0.32% |
| EBITDA | 41.76% | 12.98% | 5.83% | 7.48% | 0.82% |
| EPS Basic | 47.12% | 23.49% | 15.84% | 16.62% | 5.90% |
| Normalized Basic EPS | 45.95% | 23.22% | 15.52% | 16.34% | 8.53% |
| EPS Diluted | 47.13% | 23.53% | 15.94% | 16.65% | 5.85% |
| Normalized Diluted EPS | 45.95% | 23.22% | 15.52% | 16.34% | 8.53% |
| Average Basic Shares Outstanding | 14.91% | 13.19% | 9.71% | 6.20% | 2.37% |
| Average Diluted Shares Outstanding | 14.95% | 13.19% | 9.71% | 6.20% | 2.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |